Chimerix, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products and clinical research.
“Data from this pivotal animal model study support the potential to advance brincidofovir as a medical countermeasure for smallpox. There is currently no antiviral approved to treat smallpox, considered a Category A Priority Pathogen by the National Institute of Allergy and Infectious Diseases (NIAID). We look forward to working closely with the FDA and BARDA to contribute to the U.S. national security and public health preparedness,” said M. Michelle Berrey, MD, MPH, President and CEO of Chimerix.
Chimerix, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC. [Source: MarketWatch]
Company Website: http://www.chimerix.com